ClinicalTrials.gg
WithdrawnNCT03481894Updated Sep 4, 2019

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

A Phase 4 interventional study of Kabiven® and Compounded standard parenteral nutrition in Malnutrition, sponsored by Fresenius Kabi. Withdrawn at 2 sites in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2019-09-04.

Sponsored by Fresenius Kabi · Phase 4, Interventional, and Supportive care

Why this study was withdrawn
FDA released Fresenius Kabi from this post marketing requirement on 07/16/2019.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies in Malnutrition by Fresenius Kabi — 4 open to participants now, 4 under way, none of them phase 3. Malnutrition · Fresenius Kabi.

Started
2018
with 1 other
Phase 4
5 of 13
1 open now
Registered
3rd of 13
by date

Among the 13 studies in Malnutrition by Fresenius Kabi, this one is one of 2 that started in 2018, is one of 5 in phase 4, and was the 3rd registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 232 are open to participants now.

Browse Malnutrition studies →

Open to participants now

4 of the 13 studies in Malnutrition by Fresenius Kabi are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 151 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 45 (30%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Malnutrition by Fresenius Kabi, or all of them as a file.
02

Study summary

Demonstrate the safety and efficacy of Kabiven compared to standard parenteral nutrition (PN) administered via central vein in pediatric patients (2 to 16 years of age) requiring PN to meet nutritional needs.

03

Conditions studied

  • Malnutrition

Browse trials for

Keywords

  • Parenteral nutrition
  • Malnutrition
  • Pediatrics
  • nutritional needs
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 2 to 16 years of age
  • Patients who require at least 80% of their caloric intake as PN at study start, and in whom an indication for PN is expected for at least 5 days
  • Patients who require a central venous line to receive PN or already have a central venous line in place for other reasons
  • Written from legal representative(s)

Exclusion criteria

Exclusion Criteria:

  • Known to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or
  • Severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration >1,000 g/dL).
  • Inborn errors of amino acid metabolism
  • Cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support)
  • Hemophagocytic syndrome.
  • PN in the last 7 days prior to study enrollment.
  • Need for chronic PN before study start
  • Liver enzymes (either , ALT, GGPT), or direct exceeding 2 x
  • Pathologically altered level of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate) unless corrected prior to the start of study treatment
  • Pathologically altered blood pH, or oxygen saturation, or carbon dioxide unless corrected prior to the start of study treatment
  • Pregnancy or lactation
  • Participation in another clinical study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Kabiven®

    Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.

    Drug: Kabiven®

  • Active comparator
    Compounded standard parenteral nutrition

    The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) \<797\> "Pharmaceutical Compounding-Sterile Preparations".

    Drug: Compounded standard parenteral nutrition

Interventions

  • DrugKabiven®

    Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories. The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours. Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.

    Also known as: Kabiven® for intravenous use (investigational drug)

  • DrugCompounded standard parenteral nutrition

    Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories. The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours. Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.

    Also known as: Compounded standard parenteral nutrition (control drug)

06

What researchers measure

Primary outcomes

  1. All adverse events (AE)

    Time frame: After randomization until Day 9

  2. Vital signs: blood pressure

    Time frame: Day 1 - 9

  3. Vital signs: heart rate

    Time frame: Day 1 - 9

  4. Vital signs: body temperature

    Time frame: Day 1 - 9

  5. Vital signs: respiratory rate

    Time frame: Day 1 - 9

  6. Vital signs: saturation of peripheral oxygen (spO2)

    Time frame: Days 1-9

  7. Urine volume

    Time frame: Days 1-9

  8. Change from baseline urea nitrogen on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  9. Change from baseline alanine aminotransferase (ALT) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  10. Change from baseline aspartate aminotransferase (AST) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  11. Change from baseline direct bilirubin on days 2, 5 and 9 on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  12. Change from baseline total bilirubin on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  13. Change from baseline gamma-glutamyl transpeptidase (GGTP) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  14. Change from baseline alkaline phosphatase (ALP) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  15. Change from baseline creatinine on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  16. Change from baseline electrolytes (sodium, potassium, magnesium, calcium, chloride, phosphate) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  17. Change from baseline osmolarity on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  18. Change from baseline pH on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  19. Change from baseline glucose on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  20. Change from baseline triglycerides on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  21. Change from baseline cholesterol on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  22. Change from baseline lipase on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  23. Change from baseline amylase on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  24. Change from baseline total protein on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  25. Change from baseline c-reactive protein (CRP) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  26. Change from baseline white blood cells (WBC) count on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  27. Change from baseline platelet count on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  28. Change from baseline red blood cells (RBC) count on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  29. Change from baseline hemoglobin (hgb) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  30. Change from baseline Hematocrit (hct) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  31. Change from baseline international normalized ratio (INR) on days 2, 5 and 9

    Time frame: Days 1, 2 (or if not done: Day 3), 5, 9

  32. Nosocomial infection

    Number of health care associated infections

    Time frame: After randomization until Day 9

  33. Need for renal replacement therapy

    Time frame: Days 1-9

  34. Duration of renal replacement therapy

    Time frame: Days 1-9

  35. Need for mechanical ventilation

    Time frame: Days 1-9

  36. Duration of mechanical ventilation

    Time frame: Days 1-9

  37. Change from baseline body weight on days 5 and 9

    Time frame: Days 1, 5, 9

  38. Change from baseline albumin on days 5 and 9

    Time frame: Days 1, 5, 9

  39. Change from baseline prealbumin on days 5 and 9

    Time frame: Days 1, 5, 9

  40. Change from baseline transferrin on days 5 and 9

    Time frame: Days 1, 5, 9

  41. Change from baseline alpha linolenic acid on days 5 and 9

    Time frame: Days 1, 5, 9

  42. Change from baseline linoleic acid on days 5 and 9

    Time frame: Days 1, 5, 9

  43. Change from baseline arachidonic acid on days 5 and 9

    Time frame: Days 1, 5, 9

  44. Change from baseline eicosatrienoic (mead) acid on days 5 and 9

    Time frame: Days 1, 5, 9

  45. Change from baseline triene/tetraene ratio (Holman index) on days 5 and 9

    Time frame: Days 1, 5, 9

07

Study locations

2 sites
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2018; primary completion for Mar 2020, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2015
First posted
Mar 29, 2018
StartEst.
Mar 2018
Primary completionEst.
Mar 2020
CompletionEst.
Mar 2021
Last update
Sep 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03481894
Lead sponsor
Fresenius Kabi
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 2018 (estimated)
Primary completion
Mar 2020 (estimated)
Completion
Mar 2021 (estimated)
Last update
Sep 4, 2019

Study contacts

Joel D Lim, MD
principal investigator · Children's Mercy Hospital, Kansas City, MO 64108

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion